Skip to main content
SpringerLink
Log in

Palivizumab's value for RSV prophylaxis in high-risk infants varies

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palivizumab's value for RSV prophylaxis in high-risk infants varies. Pharmacoecon. Outcomes News 296, 6 (2001). https://doi.org/10.1007/BF03269078

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03269078

Keywords

Search

Navigation